Executive Overview
Venture capital markets across the United States experienced a measured shift in momentum, with investors scaling back the sheer frequency of multi-hundred-million-dollar mega-rounds. While the aggregate deployment of capital remains robust, the hyper-aggressive pace of mega-financings seen earlier in the decade made room for a more strategic, disciplined approach.
For the week of October 10–16, 2026, only two startups managed to secure funding rounds in the multiple hundreds of millions of dollars. Topping the weekly leaderboard was artificial intelligence infrastructure heavyweight Modal Labs, which commanded a massive $750 million Series D financing. Hot on its heels was construction automation pioneer Icon, securing a $200 million growth injection.
Despite the contraction in hyper-scale rounds, innovation showed no signs of slowing down. Capital successfully rotated into a diverse array of high-potential sectors, including cutting-edge biotech, advanced RNA and gene therapeutics, healthcare AI workflows, specialized climate insurance, and next-generation semiconductor systems.
This weekly rundown evaluates the top 10 announced funding rounds for U.S.-based companies, analyzing the macro-trends, investor motivations, and market signals defining the current venture landscape.
Detailed Chronology: The Week’s Top 10 U.S. Funding Rounds
1. Modal Labs | $750 Million (Series D)
- Sector: AI Infrastructure & Cloud Computing
- Headquarters: New York, N.Y.
- Lead Investor: Accel
- Valuation: $15.75 billion
Modal Labs captured the lion’s share of weekly venture funding, securing $750 million in a Series D round led by Accel. The financing values the New York-based cloud infrastructure provider at an impressive $15.75 billion. Modal Labs has established itself as an indispensable utility for developers deploying and scaling AI inference and complex applications. Proving its massive market adoption, the company announced alongside the funding that it has recently surpassed an annualized revenue run rate of $1 billion, setting a high watermark for infrastructure software.
2. Icon | $200 Million (Series D)
- Sector: Construction Technology & Robotics
- Headquarters: Austin, Texas
- Lead Investors: Baillie Gifford, BlackRock
Austin-based Icon continues to revolutionize the real estate and construction sectors through advanced robotic building systems and proprietary 3D-printing technology. The unicorn closed a $200 million Series D round co-led by institutional giants Baillie Gifford and BlackRock. With global housing shortages mounting and labor costs rising, Icon’s technology has garnered intense market validation; the company reports it is currently tracking toward an astonishing 4x revenue growth trajectory for 2026.
3. Soufflé Therapeutics | $135 Million (Series B)
- Sector: RNA Therapeutics & Biotechnology
- Headquarters: Boston, Mass.
- Lead Investor: Juvia Group
Biotechnology innovation claimed the third spot on the weekly ledger. Boston-based Soufflé Therapeutics successfully closed a $135 million Series B financing round. Led by Juvia Group and backed by a robust syndicate of life sciences investors, the capital will accelerate Soufflé’s pioneering pipeline of RNA-based therapies designed to address previously undruggable genetic targets.
4. Estuary Biotherapeutics | $103 Million (Series A & Seed)
- Sector: Genetic Medicines & Nephrology
- Headquarters: Menlo Park, Calif.
- Lead Investor: RA Capital Management
Erupting from stealth with significant financial backing, Menlo Park-based Estuary Biotherapeutics officially launched with $103 million in total financing. The capital stack comprises $93 million in a Series A round led by life sciences powerhouse RA Capital Management, supplemented by $10 million in previously undisclosed seed capital. Estuary is dedicated to developing targeted genetic medicines specifically tailored for patients suffering from severe and chronic kidney diseases.
5. Labelbox | $100 Million (Series E)
- Sector: AI Data Tooling & Agentic Workflows
- Headquarters: San Francisco, Calif.
- Lead Investor: Infinitum Partners
Labelbox, a foundational pillar in the AI training ecosystem, secured a $100 million Series E round led by Infinitum Partners. Over its eight-year history, the San Francisco-based company has built mission-critical software utilized by enterprises to train, evaluate, and fine-tune complex machine learning models. The new capital will specifically fuel the expansion of Labelbox’s tools designed to deploy and optimize autonomous AI agents that improve iteratively through real-world experience.
6. Suki | $90 Million (Series E)
- Sector: Healthcare AI & Clinical Workflow Automation
- Headquarters: Redwood City, Calif.
- Lead Investors: Healthier Capital, Crosslink Capital
Alleviating administrative burnout in the medical field, Redwood City-based Suki raised a $90 million Series E round. Backed by specialized healthcare and technology funds, including Healthier Capital and Crosslink Capital, Suki provides ambient AI solutions that seamlessly convert clinical conversations into structured medical documentation, precise billing codes, and health system intelligence.
7. Abby Care | $82 Million (Series C)
- Sector: Caregiver Platforms & HealthTech
- Headquarters: San Francisco, Calif.
- Lead Investor: Transformation Capital
Highlighting the growing convergence of technology and home-based care, San Francisco-based Abby Care closed an $82 million Series C funding round led by Transformation Capital. Abby Care’s platform empowers family members to become certified, professionally trained, and paid caregivers, enabling high-quality care delivery directly within the home setting for individuals with specialized developmental and medical needs.
8. Stand | $70 Million (Series C)
- Sector: Climate Insurtech
- Headquarters: San Francisco, Calif.
- Lead Investor: Saga Ventures Management
- Valuation: $1.0 billion
Operating in an increasingly vital sector driven by climate volatility, Stand secured $70 million in a Series C round that officially elevates the three-year-old startup to unicorn status at a $1.0 billion valuation. Led by Saga Ventures Management, San Francisco-based Stand specializes in underwriting and providing comprehensive home insurance solutions for properties located in high-risk zones vulnerable to natural disasters.
9. Mueon Corp. | $65 Million (Series A)
- Sector: Semiconductor Systems & Hyperscale Hardware
- Headquarters: Portland, Oregon
- Lead Investor: Maverick Silicon
To power the insatiable hardware demands of next-generation AI and hyperscale cloud environments, Portland-based Mueon Corp. completed a $65 million Series A round. Led by Maverick Silicon, Mueon is building an innovative, modular semiconductor platform engineered to dramatically enhance computing efficiency, throughput, and thermal performance at scale.
10. North.cloud | $60 Million (Series B)
- Sector: AI Spend Management & Cloud Optimization
- Headquarters: New York, N.Y.
- Lead Investor: Peakspan Capital
Rounding out the top ten, New York-based North.cloud closed a $60 million Series B round led by Peakspan Capital. As enterprise cloud and AI infrastructure bills skyrocket, North.cloud’s infrastructure spend intelligence and automation platform provides corporations with real-time analytics, budgeting visibility, and automated optimization tools to curb runaway operational expenditures.
Supporting Context & Market Metrics
The Maturation of the AI Ecosystem
The concentration of capital at the top—exemplified by Modal Labs’ $750 million infusion and Labelbox’s $100 million round—reveals a structural evolution in how investors view artificial intelligence. Early venture cycles were characterized by speculative bets on foundation model builders. Today, capital has pivoted decisively toward infrastructure providers, specialized tooling, data curation, and spend management platforms. Investors are no longer merely betting on the intelligence of the model; they are financing the toll roads, utilities, and plumbing required to keep the AI economy operational.
Resiliency in Biotech and Life Sciences
The strong showings by Soufflé Therapeutics ($135 million) and Estuary Biotherapeutics ($103 million) underscore a broader industry revival in biotech venture funding. Despite macroeconomic pressures over recent years, specialized venture funds equipped with deep scientific expertise continue to deploy capital into genetic medicines, RNA modalities, and precision nephrology. These rounds demonstrate that breakthrough scientific platforms with clear clinical milestones remain insulated from broader consumer technology sentiment swings.
Climate and Real Estate Technology Adaptation
The emergence of high-value rounds in unconventional sectors—such as Icon’s $200 million construction automation raise and Stand’s $70 million climate insurtech valuation milestone—points to a structural realignment of venture capital toward real-world physical problems. As housing affordability crises collide with climate change and natural disaster escalation, technology startups addressing structural supply and risk management are commanding premium valuations.
Official Statements and Industry Insights
Market observers and venture capitalists note that the contraction in the total volume of mega-rounds is not necessarily a sign of weakness, but rather a symptom of market discipline.
"We are witnessing a maturation of the venture ecosystem," noted an industry analyst tracking enterprise tech trends. "Founders are no longer able to rely purely on valuation hype. Investors are scrutinizing unit economics, annualized revenue run rates, and tangible enterprise utility. When a company like Modal Labs crosses a billion-dollar run rate, it justifies a massive valuation. For everyone else, the bar to entry has been permanently raised."
In the healthcare and biotech sectors, investors emphasize the long-term demographic tailwinds driving capital allocation. Platforms like Suki and Abby Care reflect an urgent necessity to leverage artificial intelligence and digital workflows to alleviate labor shortages within clinical environments and home care ecosystems.
Future Outlook: What to Expect in Late 2026
As the fourth quarter of 2026 unfolds, venture capital markets are expected to maintain a bifurcated rhythm. Mega-rounds will likely remain selective, reserved strictly for category-defining market leaders that demonstrate exceptional revenue velocity—such as Modal Labs and Icon.
Concurrently, early-to-growth stage companies across specialized verticals—particularly climate adaptation tech, automated construction, specialized health AI, and next-generation semiconductors—will continue to attract targeted syndicates. Founders entering the market must prioritize clear pathways to profitability, resilient unit economics, and deep product-market fit to secure funding in an increasingly rigorous macroeconomic climate.
Methodology
This report tracks the largest announced venture capital rounds captured in the Crunchbase database raised by U.S.-based companies between October 10 and October 16, 2026. While the Crunchbase dataset maintains near-comprehensive coverage of announced transactions, minor reporting time lags may apply for rounds finalized late in the weekly reporting window.
